TABLE 1.
Patient demographic and disease characteristics at baseline
| Characteristic | Pembrolizumab + pemetrexed‐platinum (n = 25) | Placebo + pemetrexed‐platinum (n = 15) |
|---|---|---|
| Age, median (range), y | 64.0 (34‐77) | 66.0 (34‐74) |
| Male | 19 (76) | 12 (80) |
| ECOG PS | ||
| 0 | 15 (60) | 9 (60) |
| 1 | 10 (40) | 6 (40) |
| Histology | ||
| Adenocarcinoma | 23 (92) | 14 (93) |
| NSCLC NOS | 1 (4) | 0 (0) |
| Other | 1 (4) | 1 (7) |
| Smoking status | ||
| Former/current smoker | 18 (72) | 12 (80) |
| Never | 7 (28) | 3 (20) |
| Brain metastases | 4 (16) | 5 (33) |
| PD‐L1 TPS | ||
| <1% | 14 (56) | 6 (40) |
| ≥1% | 10 (40) | 6 (40) |
| Not evaluable | 1 (4) | 3 (20) |
| Prior therapy | ||
| Neoadjuvant therapy | 0 | 0 |
| Adjuvant therapy | 3 (12) | 3 (20) |
| Prior radiationa | 8 (32) | 4 (27) |
Data are n (%) unless otherwise noted.
ECOG PS, Eastern Cooperative Oncology Group performance status; NSCLC NOS, non–small‐cell lung cancer not otherwise specified; PD‐L1, programmed death ligand 1; TPS, tumor proportion score.
a
No patient had prior thoracic radiation.